{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:21:49Z","timestamp":1780579309523,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.esmoop.2021.100236","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T13:01:40Z","timestamp":1629723700000},"page":"100236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11)"],"prefix":"10.1016","volume":"6","author":[{"given":"E.H.","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-A.","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.H.","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.S.","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-H.","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2021.100236_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2021.100236_bib2","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJMoa050518","article-title":"Effect of screening and adjuvant therapy on mortality from breast cancer","volume":"353","author":"Berry","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2021.100236_bib3","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.3816\/CBC.2004.s.003","article-title":"Gemcitabine and taxanes as a new standard of care in breast cancer","volume":"4","author":"Yardley","year":"2004","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.esmoop.2021.100236_bib4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/03602530902741828","article-title":"Clinical pharmacology and pharmacogenetics of gemcitabine","volume":"41","author":"Wong","year":"2009","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.esmoop.2021.100236_bib5","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.2012.45.2490","article-title":"Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02","volume":"31","author":"Park","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100236_bib6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejca.2017.10.002","article-title":"Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer","volume":"86","author":"Park","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2021.100236_bib7","series-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Breast Cancer","author":"Network","year":"2021"},{"key":"10.1016\/j.esmoop.2021.100236_bib8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.lungcan.2008.04.010","article-title":"Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients","volume":"63","author":"Soo","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2021.100236_bib9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/1078-0432.CCR-09-1555","article-title":"Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity","volume":"16","author":"Okazaki","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100236_bib10","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2217\/pgs.12.82","article-title":"Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine","volume":"13","author":"Woo","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.esmoop.2021.100236_bib11","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ejca.2013.11.028","article-title":"Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy","volume":"50","author":"Lee","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2021.100236_bib12","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1002\/cncr.25282","article-title":"Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer","volume":"116","author":"Tanaka","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2021.100236_bib13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/FPC.0b013e32834dd7e2","article-title":"Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer","volume":"22","author":"Li","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.esmoop.2021.100236_bib14","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1634\/theoncologist.12-6-622","article-title":"An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients","volume":"12","author":"Rha","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2021.100236_bib15","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1200\/JCO.2008.17.4839","article-title":"Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer","volume":"27","author":"Chew","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100236_bib16","first-page":"255","article-title":"Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patients","volume":"8","author":"Wong","year":"2011","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.esmoop.2021.100236_bib17","doi-asserted-by":"crossref","first-page":"100019","DOI":"10.1016\/j.esmoop.2020.100019","volume":"6","author":"Pellegrino","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2021.100236_bib18","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/FTD.0b013e318040b1fe","article-title":"Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity","volume":"29","author":"Cho","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.esmoop.2021.100236_bib19","doi-asserted-by":"crossref","first-page":"32027","DOI":"10.1038\/srep32027","article-title":"Prognostic significance of nuclear expression of UMP-CMP kinase in triple negative breast cancer patients","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.esmoop.2021.100236_bib20","doi-asserted-by":"crossref","first-page":"7050","DOI":"10.1158\/0008-5472.CAN-08-0405","article-title":"Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression","volume":"68","author":"Li","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100236_bib21","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.21037\/atm-20-5492","article-title":"TLE2 is associated with favorable prognosis and regulates cell growth and gemcitabine sensitivity in pancreatic cancer","volume":"8","author":"Hu","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.esmoop.2021.100236_bib22","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/MPA.0b013e3182a23ae4","article-title":"A\u00a0meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers","volume":"42","author":"Wei","year":"2013","journal-title":"Pancreas"},{"key":"10.1016\/j.esmoop.2021.100236_bib23","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1158\/1078-0432.CCR-04-0224","article-title":"The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma","volume":"10","author":"Spratlin","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100236_bib24","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/1078-0432.CCR-08-2080","article-title":"Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma","volume":"15","author":"Mar\u00e9chal","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100236_bib25","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/0008-5472.CAN-05-4203","article-title":"Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine","volume":"66","author":"Giovannetti","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100236_bib26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.gastro.2008.09.067","article-title":"Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer","volume":"136","author":"Farrell","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.esmoop.2021.100236_bib27","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2217\/pgs.12.81","article-title":"Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors","volume":"13","author":"Mitra","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.esmoop.2021.100236_bib28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bbrc.2012.03.122","article-title":"DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells","volume":"421","author":"Saiki","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.esmoop.2021.100236_bib29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.bjc.6603559","article-title":"Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells","volume":"96","author":"Nakano","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2021.100236_bib30","first-page":"2205","article-title":"Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer","volume":"28","author":"Ohhashi","year":"2008","journal-title":"Anticancer Res"},{"key":"10.1016\/j.esmoop.2021.100236_bib31","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1349-7006.2004.tb03257.x","article-title":"Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer","volume":"95","author":"Achiwa","year":"2004","journal-title":"Cancer Sci"},{"key":"10.1016\/j.esmoop.2021.100236_bib32","doi-asserted-by":"crossref","first-page":"81394","DOI":"10.18632\/oncotarget.19037","article-title":"DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study","volume":"8","author":"Woo","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2021.100236_bib33","doi-asserted-by":"crossref","first-page":"e2936","DOI":"10.1097\/MD.0000000000002936","article-title":"dCK expression and gene polymorphism with gemcitabine chemosensitivity in patients with pancreatic ductal adenocarcinoma: a strobe-compliant observational study","volume":"95","author":"Xiong","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.esmoop.2021.100236_bib34","doi-asserted-by":"crossref","first-page":"5200","DOI":"10.1002\/cncr.25303","article-title":"Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma","volume":"116","author":"Mar\u00e9chal","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2021.100236_bib35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0027-5107(96)00011-5","article-title":"Mutational spectra induced under distinct excision repair conditions by the 3 methylating agents N-methyl-N-nitrosourea, N-methyl-N\u02b9-nitro-N-nitrosoguanidine and N-nitrosodimethylamine in postmeiotic male germ cells of Drosophila","volume":"352","author":"Nivard","year":"1996","journal-title":"Mutat Res"},{"key":"10.1016\/j.esmoop.2021.100236_bib36","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1158\/1541-7786.MCR-05-0118","article-title":"A\u00a0novel role of DNA polymerase eta in modulating cellular sensitivity to chemotherapeutic agents","volume":"4","author":"Chen","year":"2006","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100236_bib37","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1158\/1078-0432.CCR-08-1227","article-title":"Polymerase eta mRNA expression predicts survival of non-small cell lung cancer patients treated with platinum-based chemotherapy","volume":"15","author":"Ceppi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100236_bib38","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1158\/0008-5472.CAN-04-0603","article-title":"Altered DNA polymerase iota expression in breast cancer cells leads to a reduction in DNA replication fidelity and a higher rate of mutagenesis","volume":"64","author":"Yang","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100236_bib39","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/humu.20732","article-title":"Discovery of genetic profiles impacting response to chemotherapy: application to gemcitabine","volume":"29","author":"Jarjanazi","year":"2008","journal-title":"Hum Mutat"},{"key":"10.1016\/j.esmoop.2021.100236_bib40","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921001976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921001976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:27:15Z","timestamp":1761856035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921001976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2059702921001976"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100236","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11)","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100236","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100236"}}